Search Results
Dec 26, 2025, 14:45 ET Sidus Space Announces Pricing of Offering
solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid
More news about: Sidus Space, Inc.
Dec 25, 2025, 04:02 ET Gene Solutions 於 ESMO Asia Congress 2025 成功舉辦 AI 驅動多組學液態活檢專題研討會，並榮獲兩項最佳海報獎
阮黎當醫師（越南醫學遺傳研究所），以及 Aya El Helali 教授（香港大學，香港特別行政區）。研討會重點議題包括：大規模早期檢測（SPOT-MAS）：僅需 10 mL 血液的多組學檢測，結合基因、表觀遺傳及片段組學特徵，透過高深度靶向與低深度全基因組定序完成分析。該模型基於超過 20,000 名癌症患者及 25,000 名健康人的數據進行訓練，並納入回溯性（K-DISCOVERY）與前瞻性（K-DETEK）研究隊列，涵蓋超過 11,000 名無症狀個體，且已於六個亞洲國家在超過
More news about: Gene Solutions Genomics Pte Ltd
Dec 24, 2025, 13:18 ET Sidus Space Announces Closing of Public Offering
solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid
More news about: Sidus Space, Inc.
Dec 24, 2025, 09:02 ET Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
curative salvage therapy. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA level between 0.2 and 0.75 ng/mL.The results to be presented by Prof Emmett at the EAU Congress 2026 will expand on the earlier findings that the trial met its primary endpoint,
More news about: Clarity Pharmaceuticals
Dec 24, 2025, 08:30 ET Eastern International Ltd. Entered into Contract for its First Photovoltaic Power Generation Construction Project With a Total Contract Price of RMB 42.5 Million (approximately US$ 6.04 million)
first-photovoltaic-power-generation-construction-project-with-a-total-contract-price-of-rmb-42-5-million-approximately-us-6-04-million-302649145.htmlSOURCE Eastern International Ltd.
More news about: Eastern International Ltd.
Dec 24, 2025, 08:04 ET Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide mesylate
The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically significant (P-value = 0.0005), which exceeded the pre-specified success criterion.Leuprolide
More news about: Foresee Pharmaceuticals Co., Ltd.
Dec 23, 2025, 11:28 ET Skincare nas férias: saiba como montar um nécessaire para levar na mala de viagem
Cetaphil® Gel Creme de Rápida Absorção 236ml combina de maneira única a hidratação intensa de um creme, com a sensação leve e não pegajosa2 de um gel de rápida absorção para deixar
More news about: Galderma
Dec 23, 2025, 08:00 ET ShengShu Technology and Tsinghua University Unveil TurboDiffusion, Ushering in the Era of Real-Time AI Video Generation
https://github.com/thu-ml/TurboDiffusion SageAttention: https://github.com/thu-ml/SageAttention Sparse-Linear Attention:
More news about: ShengShu Technology
Dec 22, 2025, 21:19 ET Sidus Space Announces Pricing of Public Offering
solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid
More news about: Sidus Space
Dec 22, 2025, 16:43 ET Sidus Space Announces Proposed Public Offering
solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid
More news about: Sidus Space, Inc.
Dec 22, 2025, 09:12 ET Tanabe Pharma America Announces Transfer of RADICAVA® Business to Shionogi
cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after taking
More news about: Tanabe Pharma America
Dec 22, 2025, 08:32 ET Sidus Space Awarded Contract Under Missile Defense Agency's SHIELD IDIQ Program
delivery of innovative capabilities to the warfighter with increased speed and agility. It leverages artificial intelligence and machine learning (AI/ML) enabled applications where applicable and maximizes the use of digital engineering, open systems architectures, model-based systems engineering, and
More news about: Sidus Space
Dec 22, 2025, 08:00 ET Manulife Selects Adaptive ML as Reinforcement Learning Engine to Scale Enterprise AI
Dec. 22, 2025 /PRNewswire/ - Manulife announced today that it has chosen Adaptive ML to provide model fine-tuning technology as part of its enterprise AI platform. Adaptive ML, a New York-based private AI software company, provides a reinforcement‑learning‑powered engine to fine‑tune,
More news about: Manulife Financial Corporation
Dec 22, 2025, 08:00 ET Manulife Selects Adaptive ML as Reinforcement Learning Engine to Scale Enterprise AI
Dec. 22, 2025 /CNW/ - Manulife announced today that it has chosen Adaptive ML to provide model fine-tuning technology as part of its enterprise AI platform. Adaptive ML, a New York-based private AI software company, provides a reinforcement‑learning‑powered engine to fine‑tune,
More news about: Manulife Financial Corporation
Dec 22, 2025, 08:00 ET Manulife Selects Adaptive ML as Reinforcement Learning Engine to Scale Enterprise AI
Dec. 22, 2025 /PRNewswire/ -- Manulife announced today that it has chosen Adaptive ML to provide model fine-tuning technology as part of its enterprise AI platform. Adaptive ML, a New York-based private AI software company, provides a reinforcement‑learning‑powered engine to fine‑tune,
More news about: Manulife Financial Corporation
Dec 22, 2025, 08:00 ET Manulife selecciona Adaptive ML como motor de aprendizaje por refuerzo para escalar la IA empresarial
22 de diciembre de 2025 /PRNewswire/ -- Manulife anunció hoy que ha elegido Adaptive ML para proporcionar tecnología de ajuste fino de modelos como parte de su plataforma de IA empresarial. Adaptive ML, una empresa privada de software de IA con sede en Nueva York, proporciona un motor basado en
More news about: Manulife Financial Corporation
Dec 22, 2025, 08:00 ET Manulife wählt Adaptive ML als Reinforcement-Learning-Engine, um Unternehmens-KI zu skalieren
2025 /PRNewswire/ -- Manulife gab heute bekannt, dass das Unternehmen Adaptive ML ausgewählt hat, um im Rahmen seiner KI-Plattform für den Unternehmenseinsatz Technologie zur Modell-Feinabstimmung bereitzustellen. Adaptive ML, ein privates KI-Softwareunternehmen mit Sitz in New York, bietet eine Reinforcement-Learning-basierte
More news about: Manulife Financial Corporation
Dec 22, 2025, 08:00 ET Manuvie choisit Adaptive ML comme moteur d'apprentissage par renforcement pour développer l'IA d'entreprise
décembre 2025 /PRNewswire/ -- Manuvie a annoncé aujourd'hui qu'elle avait choisi Adaptive ML pour fournir une technologie de réglage fin des modèles dans le cadre de sa plateforme d'IA d'entreprise. Adaptive ML, une société privée de logiciels d'IA basée à New York, fournit un moteur basé sur l'apprentissage
More news about: Société Financière Manuvie
Dec 22, 2025, 07:00 ET U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
-69 mL, respectively, versus -152 mL in the placebo group.5 The respective treatment difference compared with the placebo group was 65 mL (95% CI: 30, 101) and 83 mL (95% CI: 48, 118).5 The most common adverse reactions in patients with PPF treated with JASCAYD were generally consistent
More news about: Boehringer Ingelheim
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
and an immune checkpoint inhibitor). Based on their CTC level, patients were classified into two prognostic groups: those with less than 5 CTCs per 7.5 mL of blood, defined as having indolent disease, and those with 5 or more CTCs, defined as having aggressive disease. While no significant difference in
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems gibt die Veröffentlichung der Ergebnisse der Biomarker-Analyse der PACE-Studie bekannt, die den klinischen Nutzen der CELLSEARCH® CTC-Zählung für die Behandlung eines bestimmten Subtyps von metastasiertem Brustkrebs bestätigt
Immun-Checkpoint-Inhibitor). Basierend auf ihrem CTC-Spiegel wurden die Patienten in zwei Prognosegruppen eingeteilt: diejenigen mit weniger als 5 CTCs pro 7,5 ml Blut, die als indolente Erkrankung definiert wurden, und diejenigen mit 5 oder mehr CTCs, die als aggressive Erkrankung definiert wurden. Während in
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
and an immune checkpoint inhibitor). Based on their CTC level, patients were classified into two prognostic groups: those with less than 5 CTCs per 7.5 mL of blood, defined as having indolent disease, and those with 5 or more CTCs, defined as having aggressive disease. While no significant difference in
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annuncia la pubblicazione dei risultati dello studio PACE, che mostrano il valore clinico della conta delle cellule tumorali circolanti con CELLSEARCH® in uno specifico sottotipo di carcinoma mammario metastatico
inibitore del checkpoint immunitario). In base al numero di CTC, le pazienti sono state classificate in due gruppi: quelle con meno di 5 CTC per 7,5 mL di sangue, definite come affette da malattia indolente, e quelle con 5 o più CTC, definite come affette da malattia aggressiva.Sebbene
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems anuncia la publicación de los resultados del ensayo PACE, que confirma la utilidad clínica del recuento de CTC con CELLSEARCH® en un subtipo específico de cáncer de mama metastásico
de control inmunitario). En función de su nivel de CTC, los pacientes se clasificaron en dos grupos pronósticos: aquellos con menos de 5 CTC por 7,5 ml de sangre, definidos como con enfermedad indolente, y aquellos con 5 o más CTC, definidos como con enfermedad agresiva. Aunque no se observaron diferencias
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems annonce la publication des résultats de l'essai PACE confirmant l'utilité clinique de l'énumération des CTC avec CELLSEARCH® dans pour un sous-type spécifique de cancer du sein métastatique
immunitaire). En fonction de leur taux de CTC, les patientes ont été classées en deux groupes pronostiques : celles présentant moins de 5 CTC par 7,5 ml de sang, définies comme ayant une maladie indolente, et celles présentant 5 CTC ou plus, définies comme ayant une maladie agressive. Bien qu'aucune différence
More news about: Menarini Silicon Biosystems